Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2020-08-14 Regulatory Filings
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is very short (1356 characters) and contains an 'RNS Number' header, indicating it is a regulatory news service announcement from the London Stock Exchange. The content specifically discusses a 'Price Monitoring Extension' for a security, which is a routine operational update related to trading mechanisms, not a core financial report (like 10-K, ER, or IR). Since it is a general regulatory announcement that doesn't fit the specific categories like DIV, DIRS, or MANG, the most appropriate classification is the general regulatory filing fallback category.
2020-08-14 English
Price Monitoring Extension
Interest Rate Update/Notice Classification · 1% confidence The document is very short (1360 characters) and is explicitly labeled with an 'RNS Number'. The content discusses a 'Price Monitoring Extension' related to trading on the London Stock Exchange and concludes by stating, 'This information is provided by RNS, the news service of the London Stock Exchange.' This strongly indicates a general regulatory announcement or market notice rather than a specific financial report (like 10-K, IR, or ER). Since it is a general regulatory announcement provided via the RNS service, the most appropriate classification is Regulatory Filings (RNS).
2020-08-14 English
Verona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2020
Earnings Release Classification · 1% confidence The document text explicitly states that the company 'announces financial results for the three and six months ended June 30, 2020 and provides a corporate update.' It contains detailed financial highlights, operational updates, and clinical trial progress for a specific period (six months ended June 30, 2020). This structure, focusing on comprehensive financial performance over a defined period (half-year), aligns perfectly with the definition of an Interim / Quarterly Report (IR). It is not a full Annual Report (10-K), nor is it just a brief Earnings Release (ER) or a simple announcement of a report (RPA). H1 2020
2020-08-14 English
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is very short (1356 characters) and begins with 'RNS Number : 9555V', indicating it is a regulatory news service announcement from the London Stock Exchange. The content discusses a 'Price Monitoring Extension' for a security, which is a procedural update related to trading mechanisms, not a core financial report (like 10-K, ER, or IR). Since it is a general regulatory announcement that doesn't fit the specific categories like DIRS, DIV, or MANG, the most appropriate classification is the general regulatory filing fallback category.
2020-08-12 English
Positive Covid-19 In Vitro Study Results
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number : 9549V' and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority...'. This strongly indicates a regulatory announcement disseminated via the Regulatory News Service (RNS). The content is an announcement of positive study results and the progression to the next stage of research, which is a typical corporate update. Since it is a general regulatory announcement that doesn't fit specific categories like ER, DIV, or DIRS, the most appropriate classification is the general regulatory filing category, RNS.
2020-08-12 English
Verona Pharma plc: TR-1: Standard form for notification of major holdings
Major Shareholding Notification Classification · 1% confidence The document is explicitly titled 'NOTIFICATION OF MAJOR HOLDINGS' and contains structured fields typical of regulatory filings concerning share ownership thresholds, such as 'Reason for the notification', 'Details of person subject to the notification obligation', and 'Total positions of person(s) subject to the notification obligation'. The content details the acquisition/disposal of voting rights and the resulting percentage held (9.86%). This structure strongly indicates a filing related to significant changes in share ownership, which corresponds to the Major Shareholding Notification category (MRQ).
2020-08-07 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.